Charles River Laboratories Intl. Inc vs VanEck Video Gaming and eSports ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $287.43 (market cap $13.46B), while VanEck Video Gaming and eSports ETF trades at $97.96. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| CRL | ESPO | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $282.00 | $122.30 |
52-Week Low | $145.57 | $85.25 |
Enterprise Value | $16.30B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
ESPO trades at $97.97, down 1.64% today, with a bullish technical signal from moving averages and oscillators. Key support lies at $98, with resistance at $100. The stock shows strong momentum indicators, including a 6-day ADX of 55.42 signaling a strong trend. Recent financial data is unavailable, requiring updated SEC filings for fundamental assessment.
The outlook hinges on upcoming earnings to validate growth; risks include market volatility and lack of recent financial disclosures. Analyst sentiment is cautiously optimistic given technical strength, but fundamental clarity is needed for sustained upside.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →